Abivax CEO highlights pipeline assets, including lead HIV drug

Dec 07, 2017

Abivax CEO Dr. Hartmut Ehrlich talks to Scrip senior editor Lucie Ellis about the progress and next development steps for its lead clinical-stage molecule against HIV. Abivax is developing one of the first compounds, ABX464, to demonstrate an effect on human immunodeficiency (HIV) reservoirs in Phase II clinical trials. It is a first-in-class oral small anti-viral molecule, which blocks HIV replication through a unique mechanism of action. The French company is also developing ABX464 for inflammatory bowel disease, including ulcerative colitis and Crohn’s disease. A clinical study for the drug in IBD is currently enrolling patients.

Interviewer: Lucie Ellis – Senior Writer, Pharma Intelligence In Vivo/Pink Sheet/Scrip
Interviewee: Dr. Hartmut Ehrlich – CEO, Abivax